



US006025391A

United States Patent [19]
Haerberlin et al.

[11] **Patent Number:** **6,025,391**
 [45] **Date of Patent:** **Feb. 15, 2000**

[54] **ENTERIC-COATED PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLATE**

[75] Inventors: **Barbara Haerberlin**, Riehen;
Ching-Pong Mak, Therwil, both of
 Switzerland; **Armin Meinzer**,
 Buggingen, Germany; **Jacky**
Vonderscher, Riedisheim, France

[73] Assignee: **Novartis AG**, Basel, Switzerland

[21] Appl. No.: **09/077,398**

[22] PCT Filed: **Apr. 10, 1997**

[86] PCT No.: **PCT/EP97/01800**

§ 371 Date: **May 28, 1998**

§ 102(e) Date: **May 28, 1998**

[87] PCT Pub. No.: **WO97/38689**

PCT Pub. Date: **Oct. 23, 1997**

[30] **Foreign Application Priority Data**

Apr. 12, 1996 [GB] United Kingdom 9607564
 Oct. 24, 1996 [GB] United Kingdom 9622028

[51] **Int. Cl.**⁷ **A01N 43/08**; A61G 31/34

[52] **U.S. Cl.** **514/470**; 514/8; 514/11;
 514/570; 514/576; 514/960; 514/962; 424/457;
 424/458; 424/459; 424/461; 424/462; 424/463;
 424/468; 424/474; 424/475; 424/479; 424/480;
 424/482; 424/490; 424/493; 424/494; 424/495;
 424/497

[58] **Field of Search** 424/457, 458,
 424/459, 461, 462, 463, 468, 478, 475,
 479, 480, 482, 490, 493, 494, 495, 497;
 514/8, 11, 470, 570, 571, 960, 962

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,705,894 12/1972 Gerzon et al. 260/240
 3,705,946 12/1972 Dyke et al. 424/279
 3,777,020 12/1973 Johnson 424/180
 3,825,571 7/1974 Mori et al. 260/343.3
 3,853,919 12/1974 Mori et al. 260/343.3
 3,868,454 2/1975 Johnson 424/248
 3,880,995 4/1975 Jones 424/180
 3,903,071 9/1975 Holmes 260/210
 4,005,108 1/1977 Kupchan et al. .
 4,017,647 5/1972 Ohno 427/3
 4,234,684 11/1980 Abbott et al. 435/75
 4,680,299 7/1987 Hesson 514/311
 4,686,234 8/1987 Nelson et al. 514/469
 4,725,622 2/1988 Nelson et al. 514/469
 4,727,069 2/1988 Nelson et al. 514/211
 4,753,935 6/1988 Nelson et al. 514/233.5
 4,786,637 11/1988 Allison et al. 514/233.5
 4,808,592 2/1989 Nelson et al. 514/233.5
 4,847,381 7/1989 Sutherland et al. 546/156
 4,868,153 9/1989 Allison et al. 514/470
 4,959,387 9/1990 Nelson et al. 524/469
 4,992,467 2/1991 Allison et al. 514/464

FOREIGN PATENT DOCUMENTS

704 326 3/1968 Belgium .
 815330 5/1973 Belgium .

0 281 713 9/1988 European Pat. Off. .
 0281713 9/1988 European Pat. Off. .
 551182 7/1993 European Pat. Off. .
 0691130 1/1996 European Pat. Off. .
 31237 11/1967 South Africa .
 1157099 7/1969 United Kingdom .
 1157100 7/1969 United Kingdom .
 1158387 7/1969 United Kingdom .
 1 203 328 8/1970 United Kingdom .
 1203328 8/1970 United Kingdom .
 1261060 1/1972 United Kingdom .
 2 117 238 10/1983 United Kingdom .
 2117238 10/1983 United Kingdom .
 94/01105 1/1994 WIPO .
 94/26265 11/1994 WIPO .
 94/26266 11/1994 WIPO .
 95/04627 4/1995 WIPO .
 95/09626 4/1995 WIPO .
 95/13082 5/1995 WIPO .

OTHER PUBLICATIONS

Sweeney et al., *Cancer Research* 32, pp. 1803–1809, Sep. 1972.

JF Bach et al. *The mode of action of immunosuppressive agents*, Elsevier Publisher, Amsterdam, 1985, pp. 105–174.
 Allison et al., *Springer Semin Immunopathol* (1993) 14:353–380.

Chemical Abstract 122:197032, “Enteric Immunosuppressant Compositions for the Treatment of Chron’s Disease and Ulcerative Colitis”, Mar. 1995.

EpINETTE et al. *Journal of the American Academy of Dermatology*, pp. 962–971, 1981.

Ohsugi et al. *Cancer Research* 36, pp. 2923–2927, Aug. 1976.

Franklin et al., *Biochem. J.* (1969), vol. 113, pp. 515–524.
 Mitsui et al., CA 75:150091, *Progr. Antimicrob. Anticancer Chemother.*, Proc. Int. Congr. Chemother., 6th (1970) vol. 2, pp. 130–135.

Schiantarelli et al. *Agents and Actions*, vol. 14, No. 2 (1984) pp. 247–256.

Suzuki et al. *The Journal of Antibiotics*, vol. XXIX, No. 3, pp. 275–285, 1991.

Harrison et al. *J.C.S. Perkin II*, pp. 1542–1544, 1982.

Seki et al. *Antimicrobial Agents and Chemotherapy*, vol. 33, No. 5, May 1989, pp. 773–775.

Allison et al. In: *Immunosuppressive Drugs—Development in anti-rejection therapy*, pp. 141–159, 1995.

Mitsui et al., *The Journal of Antibiotics*, Aug. 1969, pp. 358–363.

James J. Lipsky, *The Lancet* 1996; vol. 348, Nov. 16, 1996, pp. 1357–1359.

(List continued on next page.)

Primary Examiner—Frederick Krass
Attorney, Agent, or Firm—Stephen G. Kalinchak

[57] **ABSTRACT**

Disclosed are pharmaceutical compositions which have been modified to release pharmaceutically acceptable mycophenolate salts in the upper part of the intestinal tract and methods of treatment using the pharmaceutical compositions.

11 Claims, No Drawings

OTHER PUBLICATIONS

- H. Boxenbaum, *Journal of Pharmacokinetics and Biopharmaceutics*, vol. 10, No. 2, 1982, pp. 201–227.
- Eugui et al. *Scand. J. Immunol.* 33, pp. 175–183, 1991.
- Morris et al. *Transplant. Proc.* vol. 22, pp. 1659–1662 (1990).
- Lee et al., *Pharmaceutical Research*, vol. 7, No. 2, 1990, pp. 161–165, 1991.
- Boit, *Beilsteins Handbuch der Organischen Chemi*, vol. 18, Part 7, p. 6513, 1987.
- Luckenbach, *Beilstein Handbook of Organic Chemistry*, vol. 18, Part 9, p. 239, 1993.
- Makara et al., *CA* 124:139508 (abstract of *Journal Med. Chem.* 1996, 39, pp. 1236–1242.
- Suzuki et al., *CA* BA62:38453, *The Journal of Antibiotics*, Mar. 1976, vol. 29, No. 3, pp. 286–291.
- Potel, *Aus der Bakteriologischen Forschungsabteilung der Asta-Werke AG.*, pp. 527–532, 1996.
- XP 002043101 *Fester orale and perorate Arzneiformen*, pp. 356–361, 1992.
- Nature*, vol. 223, Aug. 23, 1969, pp. 848–850.
- Aisenberg, *The New England Journal of Medicine*, May 27, 1965, pp. 1114–1116.
- Marinari et al., XP 002043018, *Arch Dermatol*, vol. 113, Jul. 1977, pp. 930–931.
- XP002043019, *European Mycophenolate Mofetil Cooperative Study Group*, vol. 345, May 27, 1995, pp. 1321–1322.
- 80538 *Chemical Abstracts* vol. 73, 1970, p. 230, No. 80540w.
- Chemical Abstracts*, vol. 80, 1974, p. 338, No. 59722s.
- Chemical Abstract*, vol. 80, 1974, p. 420, No. 120748y.
- Chemical Abstract*, vol. 96, 1982, p. 646, No. 199422x.
- Chemical Abstract 7-Enzymes*, vol. 124, Nov. 11, 1996, p. 559, No. 139508w.
- 26-*Biomolecules*, vol. 96, 1982, p. 647.
- Chemical Abstract*, vol. 98, 1983, p. 564, No. 143262w.
- Chemical Abstract*, vol. 98, 1983, p. 632, No. 198004w.
- 27 *Heterocytes*, vol. 98, 1983, p. 565.
- Schnitzer, *Academic Press*, vol. 10, 1972, pp. 14–19, 24, 25, 70 and 71.
- The Lancet*, vol. 345, May 27, 1995, pp. 1323–1325.
- Sollinger, H. W., *Chem. Abstr.* 1996, 95370774, *Kidney Int'l, Supplement*, 1995, vol. 52, pp. 514–517.
- Platz et al., “A new and potent immunosuppressive agent,” *Transplantation*, vol. 51, No. 1, 1991, pp. 27–31.
- Ohsugi, et al., “Antitumor and immunosuppressive effects of mycophenolic acid derivatives”, *Cancer Rres.* vol. 36, No. 1976, pp. 2923–2927.
- Chemical Abstract* 108174f, Gerzon et al., “Mycophenolic acid and its derivatives, inhibitors of malignant tumor cell growth in warm-blooded mammals”, 1995.
- Ito et al., *Pharmacokinetics of Mycophenolic Acid in Healthy Human Volunteers*, *J. Med. Soc. Toho, Japan*, vol. 29, No. 3, 1982, pp. 412–418.
- Kajiwaru et al., *General Pharmacology of Mycophenolic Acid*, *J. Med. Soc. Toho, Japan*, vol. 29, No. 3, 1982, pp. 419–425.
- Kajiwaru et al., *Species Differences of Mycophenolic Acid, a New Drug for Psoriasis in Acute, Sub-acute and Chronic Toxicity*, *Journal of the Medical Society of Toho University*, Sep. 1, 1982.
- Ohsugi et al., *CA* 84:103774, *Arerugi*, (1975) 24 (12) pp. 820–825.
- Hasunuma, et al., *CA* 112:191604 *Abstract of Adv. Exp. Med. Biol.* (1989) 253A (*Purine Pyrimidine Metab. Man* 6, Pt. A), pp. 455–460.
- Derwent Abstract* 93–329920/41 corresponding to JP 06256182–A (1994).
- Derwent Abstract* 94–313614/39 corresponding to JP 06239740–A (1994).
- Derwent Abstract* 93–220931/28 corresponding to EP 551182–A1 (1993).
- Derwent Abstract* 84509V/49 corresponding to BE 815–330 (1974).
- Derwent Abstract* 37140T–B corresponding to BE 775785 (1972).
- Derwent Abstract* 88322 C/49 corresponding to US 4234–684 (1980).

ENTERIC-COATED PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLATE

This application is a 371 of PCT/EP97/01800, filed Apr. 10, 1997.

This invention relates to mycophenolic acid.

Mycophenolic acid, also referred to herein as MPA, was first isolated in 1896, and has been extensively investigated as a pharmaceutical of potential commercial interest. It is known to have anti-tumor, anti-viral, immunosuppressive, anti-psoriatic, and anti-inflammatory activity [see e.g. W. A. Lee et al, *Pharmaceutical Research* (1990), 7, p. 161-166 and references cited therein]. Publications have appeared on MPA as an anti-cancer agent by Lilly scientists, see e.g. M. J. Sweeney et al., *Cancer Research* (1972), 32, 1795-1802, and by ICI scientists, see e.g. GB 1,157,099 and 1,203,328 and as an immunosuppressant agent see e.g. A. Mitsui et al. *J. Antibiotics* (1969) 22, p. 358-363. In the above-mentioned article by W. A. Lee et al it is stated that attempts have been made to increase the bio-availability or specificity of MPA by making derivatives. The poor bioavailability of the acid was thought to be caused by undetermined factors such as drug complexation in the gastro-intestinal lumen, a narrow absorption window, metabolism before absorption etc. The preparation of the morpholinoethyl ester, also known as mycophenolate mofetil (sometimes referred to herein as MMF), was described which had considerably higher bioavailability than MPA (100% for MMF and 43% for MPA). This derivative has been recently introduced commercially as an immunosuppressant for the treatment or prevention of organ or tissue transplant rejection, at daily dosages of from about 200 mg to about 3 grams p.o., e.g. about 2 g p.o. Patient compliance with MMF is not ideal, inter alia, because of side-effects e.g. gastro-intestinal side effects, the origin of which is not known.

We have now found, after exhaustive testing, that mycophenolate salts when enteric coated or adapted to be released in the upper part of the intestines, e.g. in the duodenum, jejunum and/or ileum, are effective, well-tolerated, pharmaceuticals particularly for immunosuppressive indications especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the treatment or prevention of immune-mediated diseases (autoimmune diseases) and have interesting bioavailability and stability characteristics. Moreover fewer unit dosage forms are required to be administered than for MMF, leading to easier administration.

The present invention provides in one aspect a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract (hereinafter referred to as a composition of the invention). The composition may be adapted in any conventional manner, preferably with means adapted to prevent release of the mycophenolate in the stomach and to ensure release in the upper part of the intestinal tract. In a further aspect the invention provides a pharmaceutical composition comprising a coated pharmaceutically acceptable mycophenolate salt.

Such salts are cationic salts, e.g. of alkali metals, especially the sodium salts. Sodium mycophenolate salts are known, e.g. in South African Patent 68/4959. We prefer to use the mono-sodium salt. This may be obtained in crystalline form by recrystallization from acetone/ethanol if necessary with water; Mpt. 189-191° C.

The invention provides, more specifically, a solid enteric-coated composition in unit dose form for oral application, the core of the composition containing sodium mycophenolate in solid or liquid form.

The term "core" comprises sodium mycophenolate (or other cationic salt) if desired in admixture with further physiologically acceptable material, that can be surrounded by an enteric-coating. The term "core" comprises, in a wide sense, not only tablets, pellets or granules but also capsules, e.g. soft or hard capsules of gelatine or starch. Such cores may be produced in conventional manner. We have found that the mycophenolate salts, particularly the sodium salt, are particularly interesting for the production of tablets. When tablet cores are used they have preferably a hardness of from ca. 10 to 70 N.

The pellets or granules may, after application of the enteric-coating as described hereinafter may be used as such or to fill capsules, e.g. hard gelatine capsules. If desired the capsules may be alternatively enteric-coated, e.g. in conventional manner.

Other pharmaceutically acceptable ingredients may be present in the cores, e.g. those conventionally used in the preparation of pharmaceutically compositions, e.g. fillers, e.g. lactose, glidants, e.g. silica, and lubricants, e.g. magnesium stearate.

The term "enteric coating" comprises any pharmaceutically acceptable coating preventing the release of the active agent in the stomach and sufficiently disintegrating in the intestine tract (by contact with approximately neutral or alkaline intestine juices) to allow the resorption of the active agent through the walls of the intestinal tract. Various *in vitro* tests for determining whether or not a coating is classified as an enteric coating have been published in the pharmacopoeia of various countries.

More specifically, the term "enteric coating" as used herein refers to a coating which remains intact for at least 2 hours, in contact with artificial gastric juices such as HCl of pH 1 at 36 to 38° C. and preferably thereafter disintegrates within 30 minutes in artificial intestinal juices such as a KH_2PO_4 buffered solution of pH 6.8.

The thickness of the coating may vary and depends inter alia on its permeability in water and acids. A typical coating may be about 16-30, e.g. 16-20 or to 25, mg on a size 1 gelatine capsule. Similar thicknesses may be applied in other formulations.

In general satisfactory results are obtained with a coating of 5-100 μm , preferably 20-80 μm thickness. The coating is suitably selected from macromolecular polymers. Suitable polymers are listed in e.g. L. Lachman et al. *The Theory and Practice of Industrial Pharmacy*, 3rd Ed, 1986, p. 365-373, H. Sucker et al, *Pharmazeutische Technologie*, Thieme, 1991, p. 355-359, Hagers *Handbuch der pharmazeutischen Praxis*, 4th Ed. Vol. 7, pages 739 to 742 and 766 to 778, (Springer Verlag, 1971) and Remington's *Pharmaceutical Sciences*, 13th Ed., pages 1689 to 1691 (Mack Publ., Co., 1970) and comprise e.g. cellulose ester derivatives, cellulose ethers, acrylic resins, such as methylacrylate copolymers and copolymers of maleic acid and phthalic acid derivatives.

The preferred films are made from cellulose acetate phthalate and trimellitate; methacrylic acid copolymers, e.g. copolymers derived from methylacrylic acid and esters thereof, containing at least 40% methylacrylic acid; and especially hydroxypropyl methylcellulose phthalate.

Methylacrylates include those of molecular weight above 100,000 daltons based on, e.g. methylacrylate and methyl or ethyl methylacrylate in a ratio of about 1:1. Typical products include Endragit L, e.g. L 100-55, marketed by Rohm GmbH, Darmstadt, Germany.

Typical cellulose acetate phthalates have an acetyl content of 17-26% and a phthalate content of from 30-40% with a viscosity of ca. 45-90 cP.

Typical cellulose acetate trimellitates have an acetyl content of 17–26%, a trimellityl content from 25–35% with a viscosity of ca. 15–20 cS. An example of an appropriate cellulose acetate trimellitate is the marketed product CAT (Eastman Kodak Company, USA).

Hydroxypropyl methylcellulose phthalates, typically have a molecular weight of from 20,000 to 100,000 daltons e.g. 80,000 to 130,000 daltons, e.g. a hydroxypropyl content of from 5 to 10%, a methoxy content of from 18 to 24% and a phthalyl content from 21 to 35%.

An example of an appropriate cellulose acetate phthalate is the marketed product CAP (Eastman Kodak, Rochester N.Y., USA).

Examples of suitable hydroxypropyl methylcellulose phthalates are the marketed products having a hydroxypropyl content of from 6–10%, a methoxy content of from 20–24%, a phthalyl content of from 21–27%, a molecular weight of about 84,000 daltons known under the trade mark HP50 and available from Shin-Etsu Chemical Co. Ltd., Tokyo, Japan, and having a hydroxypropyl content, a methoxy content, and a phthalyl content of 5–9%, 18–22% and 27–35% respectively, and a molecular weight of 78,000 daltons, known under the trademark HP55 and available from the same supplier.

A preferred coating is HP 50.

The enteric coating may be carried out in conventional manner, e.g. so that the cores are sprayed with a solution of the enteric-coating.

Suitable solvents for the enteric-coating are for example organic solvents, e.g. an alcohol such as ethanol, a ketone such as acetone, halogenated hydrocarbons such as CH_2Cl_2 or mixtures of such solvents, e.g. ethanol/acetone, e.g. 1:1 to 10:1.

Conveniently a softener such as di-n-butylphthalate or triacetin is added to such a solution, e.g. in a ratio of coating material to softener of from 1:1 about 0.05 to about 0.3.

If desired for cellulose phthalates and other acidic coating materials an ammonium salt may be found and an aqueous solution may be used.

A fluidized bed coater may be used for coating.

Conveniently the cores are treated at room temperature or warmed up to 40° C. e.g. by means of warm air of 40° up to 70° C., before spraying. To avoid a sticking of the cores the spray procedure is preferably interrupted at certain time intervals and the cores then warmed up again. It is, however, also possible to proceed without interruption of the spray procedure, e.g. by automatic regulation of the spray amount taking into account the temperature of exhaust air and/or cores.

The spray pressure may vary within wide ranges, in general satisfactory results are obtained with a spray pressure of from about 1 to about 1.5 bar.

The compositions of the invention are useful as immunosuppressants as indicated by standard tests.

The activity and characteristics of the compositions of the invention may be indicated in standard

a) clinical trials, e.g. observing the first acute rejection episodes or treatment failure six months after transplant of kidneys or maintaining a rejection-free state within 6 months after initiation of treatment with the invention. The compositions of the invention are administered at a dose in the range of 0.5 to 2.0 g/day e.g. about 1.5 g/day and decrease the acute rejection rates when administered during the period around transplant surgery, and maintain a rejection-free state in patients who are 3 months or more after transplantation. Thus the compositions of the invention may be administered during the initial 72 hours after

transplantation at dose of about 0.5 g administered twice a day in combination with a conventional steroid and cyclosporin, e.g. as NEORAL for which the cyclosporin dose is the conventional dose e.g. ca. 8 ± 3 mg/kg for renal transplants. The steroid dose is to be administered at about 2.5 mg/kg for 4 days after transplant, 1 mg/kg thereafter for 1 week, 0.6 mg/kg thereafter for 2 weeks thereafter 0.3 mg/kg for 1 month for prednisone.

and in

b) animal trials e.g. observing the kidney allograft reaction in rat. In this test one kidney from a female Fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomized WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft. Typical doses of the compositions of the invention are from about 1 to 30 mg/kg p.o.

The compositions of the invention are particularly useful for the following conditions:

a) Treatment and prevention of native or transgenic organ, tissue or cellular allograft or xenograft transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, pancreatic islet cell, neural cell or corneal transplant; including treatment and prevention of acute rejection; treatment and prevention of hyperacute rejection, e.g. as associated with xenograft rejection; and treatment and prevention of chronic rejection, e.g. as associated with graft-vessel disease. The compositions of the invention are also indicated for the treatment and prevention of graft-versus-host disease, such as following bone marrow transplantation.

b) Treatment and prevention of autoimmune diseases, e.g. immune-mediated diseases and inflammatory conditions, in particular inflammatory conditions with an etiology including an immunological component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific immune-mediated diseases for which the compositions of the invention may be employed include, autoimmune hematological disorders, including, but not limited to hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulosis, dermatomyositis, polymyositis, chronic active hepatitis, primary biliary cirrhosis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, pemphigus, idiopathic sprue, inflammatory bowel diseases (including e.g. ulcerative colitis and Crohn's disease), endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, juvenile diabetes (diabetes mellitus type I), non-infectious uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, vasculitis, glomerulonephritides (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.

Appropriate dosages of the compositions of the invention will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the MPA salt used, the effect desired and the mode of administration.

In general however satisfactory results are obtained on administration e.g. orally at dosages on the order of from

about 1 to about 30 mg salt per kg animal body weight per day, administered once or in divided doses up to 4 times per day. Suitable daily dosages for patients are thus in the order of 200 mg to 3 g p.o. salt e.g. from about 50 to 100% that of mycophenolate mofetil. For the preferred mono sodium salt the dosage of the salt is about two thirds that of mycophenolate mofetil.

Representative unit dosage forms contain from about 50 mg, e.g. 100 mg, to about 1.5 g of the pharmaceutically acceptable mycophenolate salt.

The bioavailability characteristics of compositions of the invention may be determined in conventional manner, e.g. by oral administration to beagle dogs. Dosages are typically 50 mg salt animal e.g. ca 3–5 mg salt/kg animal body weight. Dogs are adult (ca. 10 kg e.g. 6–14 kg) and fasted. Three hours after administration ca. 200 g food is administered. Blood samples are taken from the cephalic vein, before administration and 10, 30, and 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours, after administration. Plasma levels of free MPA are determined by HPLC analysis (with UV detection).

In a relative bioavailability trial as described above in male beagle dogs dosages of 3.8 mg salt/kg animal body weight p.o. were administered with the Example 1 composition as described hereinafter and with a MPA or MMF formulation corresponding to the Example 1 composition but containing an identical amount of MPA or commercially available MMF.

Results are as follows:

	Ex 1	MPA	MMF
MPA (AUC Relative Bioavailability, Frel [ng · hr · ml⁻¹])			
Mean	4612 (218)	3579 (174)	2709 (100)
Median	4204 (168)	2911 (182)	2513 (100)
SD	939	1889	1363
CV	20	53	50
C_{max} [ng/ml] (Relative C_{max})			
Mean	5391 (313)	3683 (227)	2052 (100)
Median	5359 (367)	2719 (172)	1462 (100)
SD	1847	2504	945
CV (%)	34 (46)	68 (87)	46 (0)

The coefficients of variation (CV) of AUC (20%) and C_{max} (34%) of the Example 1 composition are significantly less than those of the reference compositions, indicating less inter-subject and intra-subject variability with the Example 1 composition.

The area under the curve (AUC) and C_{max} with the Example 1 composition are higher than those of the reference compositions.

Naturally the advantageous bioavailability characteristics of the present compositions may be ascertained in standard clinical bioavailability trials. For example, doses from 200 mg to 1.5 g of the Example 1 composition and MPA, and MMF may be administered to 12 healthy volunteers in single doses in a cross-over trial. Increased AUC and C_{max} may be observed for the Example 1 composition.

The compositions of the present invention are surprisingly tolerated better than MMF, inducing less gastro-intestinal side effects such as diarrhoea and burning. They show less long term side effects e.g. in the colon.

The compositions of the invention may be administered as the sole active ingredient or with another immunosuppressant

e.g. together with simultaneous or separate administration of other immunosuppressants, for example, in immunosuppressive applications such as prevention and treatment of graft vs. host disease, transplant rejection, or immune-mediated disease, the compositions of the invention may be used in combination with cyclosporins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, FK-506 (tacrolimus), etc., rapamycin; corticosteroids; cyclophosphamide; azathioprine; methotrexate; brequinar; leflunomide; mizoribine; deoxyspergualin; analogues thereof, and immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD25, CD28, CTLA4, B7, CD45, or CS58 or their ligands; or other immunomodulatory compounds.

When the compositions of the invention are co-administered with such other immunosuppressants the dosages of the other immunosuppressants may be reduced e.g. to one-half to one-third their dosages when used alone.

Representative doses for ciclosporin to be used are e.g. 1 to 10, e.g. 1 to 2 mg/kg/day.

The present invention provides in another aspect the use, method and compositions as defined hereinafter in the claims.

Insofar as details of excipients are not described herein, these are known, or available e.g. in the Handbook of Pharmaceutical Excipients, Second Edition, edited by Ainley Wade and Paul J. Weller, American Pharmaceutical Association, Washington, USA and Pharmaceutical Press, London; and Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete edited by H. P. Fiedler, 4th Edition, Editio Cantor, Aulendorf and earlier editions.

Following is a description by way of example only of compositions of this invention:

EXAMPLE 1

COMPOSITION

Capsule contents

MPA mono sodium salt	53.43 mg (= 50 mg MPA)
Lactose (1:1 mixture of 100/200 mesh)	256.57 mg
Silica (Aerosil)	3.1 mg
Magnesium stearate	1.55 mg
	314.65 mg

Capsule is size 1

Enteric coating (ca 17 mg)

Hydroxypropyl methyl cellulose phthalate (HP50)	9 parts
Triacetin	1 part

Procedure

The capsule ingredients are mixed and filled into size 1 capsules. The capsules are coated in a fluidized bed coater with a solution of the enteric coating ingredients in ethanol (containing 10% acetone). The coating on each capsule is about 17 mg. The capsules meet the enteric coating test described herein and do not disintegrate within 2 hours in artificial gastric juices (pH 1, HCl). The compositions are stable, e.g. for 2 years at room temperature.

If desired larger capsules containing 534.3 mg MPA mono sodium salt may be made in analogous manner, reducing the amount of lactose. These are well tolerated in clinical trials.

EXAMPLE 2

Capsules of size 1 are made up as in Example 1. A solution for enteric coating is made up as follows:

Hydroxypropyl methyl cellulose phthalate (HP50)	270 g
Triacetin	30 g
Acetone	900 g
Ethanol	1800 g

600 g of this enteric coating solution are used for 1 kg of capsules (ca. 2400). The amount of coating applied to each capsule is about 25 mg giving a film thickness of 5–6 mg/cm².

We claim:

1. A pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to prevent release of the mycophenolate salt in the stomach and to release the mycophenolate salt in the upper part of the intestinal tract.
2. A pharmaceutical composition comprising an enteric coated pharmaceutically acceptable mycophenolate salt.
3. A method of immunosuppressing a subject which comprises administering a therapeutically effective amount of enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 to a subject in need of

such immunosuppression, optionally with the simultaneous or separate administration of another immunosuppressant.

4. A composition containing an enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 and another immunosuppressant for simultaneous, sequential or separate administration.

5. A pharmaceutical composition according to claim 1 wherein the mycophenolate salt is a mono-sodium salt.

6. A pharmaceutical composition according to claim 2 wherein the mycophenolate salt is a mono-sodium salt.

7. A method according to claim 3 wherein the mycophenolate salt is a mono-sodium salt.

8. A method according to claim 3 wherein said another immunosuppressant is cyclosporin.

9. A pharmaceutical composition according to claim 4 wherein the mycophenolate salt is a mono-sodium salt.

10. A pharmaceutical composition according to claim 9 wherein said another immunosuppressant is cyclosporin.

11. A pharmaceutical composition according to claim 4 wherein said another immunosuppressant is cyclosporin.

* * * * *